Establishing cost-effectiveness of genetic targeting of cancer therapies

Share/Save/Bookmark

Retèl, Valesca P. and Rutgers, E.J.Th. and Joore, M.A. and Harten, W.H. van (2011) Establishing cost-effectiveness of genetic targeting of cancer therapies. European Journal of Oncology Pharmacy, 5 (1). pp. 28-31. ISSN 1783-3914

open access
[img]
Preview
PDF
254kB
Abstract:The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to help decision-making in an uncertain time of development.
Item Type:Article
Faculty:
Management and Governance (SMG)
Research Group:
Link to this item:http://purl.utwente.nl/publications/78769
Official URL:http://www.ppme.eu/Publications/EJOP/Journal-information/Previous-issues/EJOP-Vol.5-2011-Issue-1/Feature/Establishing-cost-effectiveness-of-genetic-targeting-of-cancer-therapies
Export this item as:BibTeX
EndNote
HTML Citation
Reference Manager

 

Repository Staff Only: item control page